Back to News
Market Impact: 0.18
Citigroup Initiates Coverage of Dianthus Therapeutics with Buy Rating
Source: Nasdaq
Analyst InsightsCompany Fundamentals
Fintel reports that Citigroup initiated coverage of Dianthus Therapeutics (DNTH) on Sept. 4, 2026 with a Buy recommendation. The note is a supportive analyst action for the stock, but no valuation metrics, target price, or forecast changes were provided in the article excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
DNTH0.45
More News
- Daiwa, Mizuho clear final hurdles to launch China securities units, Bloomberg says
- LightStream stops accepting loan applications. Try these 6 lenders instead
- Citi Australia CEO on ANZ Market, Biz Growth
- Citi Global Chief Economist on Global Growth
- CNBC's The China Connection newsletter: Navigating a tech-heavy world
- 'Cannot play hide and seek': Singapore minister's warning over haze sends agricultural stocks lower